Received: 12 November 2020
Accepted: 1 January 2021
First Online: 15 January 2021
Ethics approval and consent to participate
: All methods were carried out in accordance with relevant guidelines and regulations.All experimental protocols were approved by a Juntendo University review board in accordance with the Declaration of Helsinki. The ethics application approval number was 17–206. Informed consent was obtained from all patients and all subjects were over 20 in this study.
: Not applicable.
: T.K is affiliated with a department endowed by Philips Respironics, ResMed, Teijin Home Healthcare, and Fukuda Denshi. R.N is affiliated with a department endowed by Philips Respironics, ResMed, Teijin Home Healthcare, and Fukuda Denshi. H.D received speakers’ Bureau/Honoraria from Kowa Pharmaceutical Company Ltd., Sanofi-Aventis K.K., Daiichi Sankyo Company., Takeda Pharma ceutical Co., Ltd., Bayer Yakuhin Ltd., MSD K.K., Astellas Pharma Inc., Amgen Astellas BioPharma K.K., AstraZeneca K.K., and research funds from Sanwakagaku Kenkyusho Co., Ltd., Canon Medical Systems Corporation., Kowa Pharmaceutical Company Ltd., Daiichi Sankyo Company., Abbott Medical Japan Co., Ltd., Nihon Medi-Physics Co., Ltd., and Scholarship funds from Abbott Medical Japan Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Astellas Pharma Inc., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Co., Ltd., Daiichi Sankyo Company., Takeda Pharma ceutical Co., Ltd., Abbott Medical Japan Co., Ltd., Actelion Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corporation., Teijin Pharma Ltd., that are unrelated to this study. All other authors declare no conflict of interest. These funding sources have no other roles in this study. The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.